References
- Donnez J, Dolmans MM. Uterine fibroid management: from the present to the future. Hum Reprod Update. 2016;22:665–686.
- Kim J, Sefton EC. The role of progesterone signaling in the pathogenesis of uterine leiomyoma. Mol Cell Endocrinol. 2012;358:223–231.
- Stewart EA, Nicholson WK, Bradley L, et al. The burden of uterine fibroids for African-American women: results of a national survey. J Womens Health (Larch-Rnt). 2013;22:807–816.
- Stewart EA. Clinical practice. Uterine fibroids. N Engl J Med. 2015;372(17):1646–1655.
- Lumsden MA, Hamoodi I, Gupta J, et al. Fibroids: diagnosis and management. Bmj. 2015 Oct 13;351:h4887.
- Wise LA, Laughlin-Tommaso SK. Epidemiology of uterine fibroids: from menarche to menopause. Clin Obstet Gynecol. 2016;59:2–24.
- Petraglia F, Serour GI, Chapron C. The changing prevalence of infertility. Int J Gynaecol Obstet. 2013;123(Suppl 2):S4–8.
- IMS data August 2017. Available from: www.IQVIA.com.
- Nisolle M, Gillerot S, Casanas-Roux F, et al. Immunohistochemical study of the proliferation index, oestrogen receptors and progesterone receptors A and B in leiomyomata and normal myometrium during the menstrual cycle and under gonadotrophin-releasing hormone agonist therapy. Hum Reprod. 1999;14:2844–2850.
- Bouchard P, Chabbert-Buffet N, Fauser BC. Selective progesterone receptor modulators in reproductive medicine; pharmacology, clinical efficacy and safety. Fertil Steril. 2011;96:1175–1189.
- Chabbert-Buffet EN, Bouchard P. Fibroid growth and medical options for treatment. Fertil Steril. 2014;102:630–639.
- Bestel E, Donnez J. The potential of selective progesterone receptor modulators for the treatment of uterine fibroids. Expert Rev Endocrinol Metab. 2014;9:79–92.
- Donnez J, Vázquez F, Tomaszewski J, et al. PEARL III and PEARL III Extension Study Group. Long-term treatment of uterine fibroids with ulipristal acetate. Fertil Steril. 2014;101:1565–1573.
- Donnez J, Tatarchuk TF, Bouchard P, et al. PEARL I Study Group. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 2012;366:409–420.
- Courtoy G, Donnez J, Marbaix E, et al. In vivo mechanisms of uterine myoma volume reduction with ulipristal acetate treatment. Fertil Steril. 2015;104:426–434.
- Courtoy G, Donnez J, Ambroise J, et al. Gene expression changes in the response of uterine myomas to ulipristal acetate treatment. Reprod Biomed Online. 2018. In revision.
- Courtoy G, Henriet P, Marbaix E, et al. Matrix metalloproteinase activity correlates with uterine myoma volume reduction after ulipristal acetate treatment. J Clin Endocrinol Metabolism. 2018 [Epub ahead of print].
- Mehine EK, Heinonen HR, Mäkinen N, et al. Integrated data analysis reveals uterine leiomyoma subtypes with distinct driver pathways and biomarkers. Proc Natl Acad Sci. 2016;113:1315–1320.
- Williams AR, Bergeron C, Barlox DH, et al. Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. Int J Gynecol Pathol. 2012;31:556–569.
- Donnez J, Donnez O, Matule D, et al. Long-term medical management of uterine fibroids with ulipristal acetate. Fertil Steril. 2016;105:165–173.
- Donnez J, Tomaszewski J, Vázquez F, et al. PEARL II Study Group. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med. 2012;366:421–432.
- Auritec pharm. Available from: http://www.auritecpharma.com/pipeline/
- Fauser BC, Donnez J, Bouchard P, et al. Safety after extended repeated use of ulipristal acetate for uterine fibroids. PLoS One. 2017;12:e0173523.
- Munro MG, Critchley HO, Broder MS, et al. FIGO Working Group on Menstrual Disorders. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet. 2011;113:1–2.